Bio Rad Laboratories (BIO) Rebound Puts Fair Value Questions Back In Focus

Fresh look at Bio-Rad Laboratories after recent share price move

Bio-Rad Laboratories (BIO) has drawn fresh investor attention after a recent share price move, with the stock closing at $387.70. That puts current performance in focus across its life science and clinical diagnostics segments.

Over the past month, Bio-Rad Laboratories has shown stronger momentum, with a 30 day share price return of 19.12% and a year to date share price return of 27%. However, the 5 year total shareholder return has declined 52.70%, highlighting how recent optimism contrasts with longer term investor experience.

Spot fresh momentum in Bio-Rad Laboratories, then compare it with other stocks showing strong recent performance using the hand-picked 45 high quality undervalued stocks as a starting point.

Bulls point to Bio-Rad Laboratories' recent rebound and global diagnostics footprint. Bears focus on the long term share price decline and a value score of 0. Which side do the current valuation markers lean toward next?

Most Popular Narrative: 18% Overvalued

The most followed narrative pegs fair value for Bio-Rad Laboratories at $329, which sits below the latest close of $387.70. That gap rests on a detailed set of revenue, margin, and valuation assumptions.

Resilience and stable growth in consumables and reagents, demonstrated by high single-digit growth, especially in the face of delayed academic and instrument funding, are shifting Bio-Rad's sales mix toward higher-margin, recurring revenues, supporting overall profitability and cash flow stability.

Read the complete narrative. Read the complete narrative.

Want to see why this narrative still supports a higher valuation multiple than many peers? The entire framework leans on modest revenue growth, slightly thinner margins, and a richer future earnings multiple that assumes the market keeps rewarding Bio-Rad Laboratories for its recurring revenue mix and buyback activity.

Result: Fair Value of $329 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to weigh softer instrument demand and pressure in Clinical Diagnostics, especially in China. These factors could keep margins and revenue under strain.

Find out about the key risks to this Bio-Rad Laboratories narrative.

Next Steps

If the mixed sentiment around Bio-Rad Laboratories leaves you unsure, take a moment to review the risk profile yourself. A useful place to start is our breakdown of 1 important warning sign

Looking for more investment ideas beyond Bio-Rad Laboratories?

If Bio-Rad Laboratories has sharpened your interest, do not stop here. Use the Simply Wall St screener to uncover other opportunities that might suit your portfolio.

• Target potential value opportunities by scanning companies with strong fundamentals using our focused 45 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with higher yields through the carefully curated 12 dividend fortresses.
• Prioritise resilience by checking companies with robust finances using the hand picked list of solid balance sheet and fundamentals (52 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com